Loading patent…
AssigneeNestlé Skin Health S.A.
InventorClaire Mallard
Estimating the term…
Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one fatty phase comprising one or more fatty compounds different from solvents and/or propenetrating agents of avermectin compounds and a least one active compound chosen from avermectin compounds, where the composition comprises neither solvents nor propenetrating agents of avermectin compounds. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.
A dermatological or pharmaceutical composition comprising:
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide: condensed with a carbocyclic ring, e.g. coumaran,…
Galenical forms characterised by the site of application: skin, i.e. galenical aspects of topical compositions
Medicinal preparations characterised by special physical form: ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Medicinal preparations characterised by special physical form: dispersions; Emulsions
About 11 years 1 month of term left · ends 23 Nov 2037 (estimated)
This application is a National Phase of International Patent Application No. PCT/EP2017/080148, filed Nov. 23, 2017, published on May 31, 2018 as WO 2018/096010 A1, which claims priority to European Patent Application No. 16306554.3, filed Nov. 24, 2016. The contents of these applications are herein incorporated by reference in their entirety.
The invention relates to a dermatological or pharmaceutical composition comprising at least one active compound chosen from avermectin compounds without solvents and propenetrating agents of avermectin compounds.
In particular, the invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one fatty phase comprising one or more fatty compounds different from solvents and/or propenetrating agents of avermectin compounds and at least one active compound chosen from avermectin compounds, where the composition comprises neither solvents nor propenetrating agents of avermectin compounds.
1) Preparation of the Compositions
The compositions 1 to 3 according to the invention are formulated according to the following procedure:
In a first beaker, weigh the carbomer polymer (Pemulen TR1) and the purified water, mix at 700 rpm and heat to 65° C. (±2° C.) then weigh the rest of the ingredients of the aqueous phase and mix all the aqueous phase.